Diasorin SpA (WBO:DIAS) Other Current Liabilities: €59 Mil (As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €69.68
GF Value €90.06
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Other Current Liabilities?

Diasorin SpA WBO:DIAS +2.47% 74 Other Current Liabilities is €59 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's other current liabilities for the quarter that ended in Dec. 2025 was €59 Mil.

Diasorin SpA's quarterly other current liabilities declined from Jun. 2025 (€134 Mil) to Sep. 2025 (€0 Mil) but then increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€59 Mil).

Diasorin SpA's annual other current liabilities declined from Dec. 2023 (€127 Mil) to Dec. 2024 (€101 Mil) and declined from Dec. 2024 (€101 Mil) to Dec. 2025 (€59 Mil).

Diasorin SpA Other Current Liabilities Related Terms

Diasorin SpA Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Other Current Liabilities Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.25 141.40 126.60 100.63 59.03

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 133.91 0.00 59.03 0.00
WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €59 Mil mean?
Diasorin SpA (WBO:DIAS) has a Other Current Liabilities of €59 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Diasorin SpA.
Is Diasorin SpA's Other Current Liabilities too high?
Diasorin SpA's current Other Current Liabilities is €59 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Other Current Liabilities compare to TMO and DHR?
Diasorin SpA's Other Current Liabilities of €59 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Diasorin SpA. Diasorin SpA's current Other Current Liabilities is €59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current Other Current Liabilities is €59 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Other Current Liabilities is €59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Other Current Liabilities: €59 Mil
  • GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.68
Price
€90.06
GF Value